A Phase 1, Open-label Study in Healthy Female Subjects to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midazolam (Probe Substrate for Cytochrome P450 3A4)
Latest Information Update: 13 Dec 2022
Price :
$35 *
At a glance
- Drugs Bersacapavir (Primary) ; Drospirenone/ethinylestradiol; Midazolam
- Indications Hepatitis B
- Focus Pharmacokinetics
- Sponsors Janssen Sciences Ireland UC
- 01 Dec 2022 Results of pooled analysis from NCT03945539, NCT03111511 assessing Drug-Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379 published in the Clinical Pharmacology in Drug Development
- 01 Sep 2017 Status changed from recruiting to completed.
- 18 Apr 2017 New trial record